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ARTICLE
The Methylenetetrahydrofolate Reductase 677CrT Polymorphism
as a Modulator of a B Vitamin Network with Major Effects
on Homocysteine Metabolism
Steinar Hustad, Øivind Midttun, Jørn Schneede, Stein Emil Vollset, Tom Grotmol, and
Per Magne Ueland
Folates are carriers of one-carbon units and are metabolized by 5,10-methylenetetrahydrofolate reductase (MTHFR) and
other enzymes that use riboﬂavin, cobalamin, or vitamin B6 as cofactors. These B vitamins are essential for the re-
methylation and transsulfuration of homocysteine, which is an important intermediate in one-carbon metabolism. We
studied the MTHFR 677CrT polymorphism and B vitamins as modulators of one-carbon metabolism in 10,601 adults
from the Norwegian Colorectal Cancer Prevention (NORCCAP) cohort, using plasma total homocysteine (tHcy) as the
main outcome measure. Mean concentrations of plasma tHcy were 10.4 mmol/liter, 10.9 mmol/liter, and 13.3 mmol/liter
in subjects with the CC (51%), CT (41%), and TT (8%) genotypes, respectively. The MTHFR 677CrT polymorphism,
folate, riboﬂavin, cobalamin, and vitamin B6 were independent predictors of tHcy in multivariate models ( ), andP ! .001
genotype effects were strongest when B vitamins were low ( ). Conversely, the MTHFR polymorphism inﬂuencedP  .006
B vitamin effects, which were strongest in the TT group, in which the estimated tHcy difference between subjects with
vitamin concentrations in the lowest compared with the highest quartile was 5.4 mmol/liter for folate, 4.1 mmol/liter for
riboﬂavin, 3.2 mmol/liter for cobalamin, and 2.1 mmol/liter for vitamin B6. Furthermore, interactions between B vitamins
were observed, and B vitamins were more strongly related to plasma tHcy when concentrations of other B vitamins were
low. The study provides comprehensive data on the MTHFR–B vitamin network, which has major effects on the transfer
of one-carbon units. Individuals with the TT genotype were particularly sensitive to the status of several B vitamins and
might be candidates for personalized nutritional recommendations.
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The ﬂavoenzyme 5,10-methylenetetrahydrofolate reduc-
tase (MTHFR [MIM 236250]) regulates the ﬂow of folates
between the production of nucleotides and the supply of
methyl groups for methionine synthesis1,2 and has major
effects on the distribution of intracellular folates.3 The
MTHFR substrate is 5,10-methylenetetrahydrofolate,
which is formed from serine and tetrahydrofolate by vi-
tamin B6–dependent serine hydroxymethyltransferase.2,4
The product of the MTHFR reaction is 5-methyltetrahy-
drofolate, which is the methyl donor in the conversion
of homocysteine to methionine catalyzed by cobalamin-
dependent methionine synthase.2,4 Methionine may be
incorporated into proteins or may serve as the precursor
of S-adenosylmethionine, a universal methyl group do-
nor, which is converted to homocysteine after demethyl-
ation.2,5 Homocysteine is metabolized through two vita-
min B–dependent pathways and may be either remethy-
lated and recycled as methionine or removed from the
remethylation cycle by undergoing irreversible B6-depen-
dent transsulfuration to form cysteine.5 This makes ho-
mocysteine a key intermediate in one-carbon metabolism
and explains why B vitamins involved in the transfer of
one-carbon units are related to plasma concentrations of
total homocysteine (tHcy).6
The 677CrT transition in the MTHFR gene (dbSNP ac-
cession number rs1801133) results in an Ala222Val sub-
stitution in the polypeptide chain,7 which is associated
with a thermolabile8 enzyme. MTHFR in lymphocytes
from subjects with the TT genotype has ∼30% of the cat-
alytic activity of the wild type, whereas the CT genotype
has 65% catalytic activity.7 Lower catalytic activity is as-
sociated with a redistribution of one-carbon substituted
folates away from 5-methyltetrahydrofolate toward more
oxidized forms, which may be used for DNA synthesis and
repair.3,4 The MTHFR polymorphism is associated with
clinical endpoints; an increased risk of cardiovascular
disease9,10 and neural tube defects (MIM 601634)11,12 and
a lower risk of colorectal cancer (MIM 114500)13–15 are
found in subjects with the variant compared with the
wild-type enzyme. The MTHFR 677CrT polymorphism is
the single most important genetic determinant of plasma
tHcy.16,17 Much of the interest in this polymorphism stems
from its association with moderate hyperhomocystein-
emia (MIM 603174), which is a risk factor for occlusive
arterial disease,18 cognitive decline,19 and osteoporosis.20,
21 It is still not clear whether these conditions are caused
by homocysteine toxicity22 or if an elevated concentration
of plasma tHcy is mainly an epiphenomenon.23–25
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Table 1. Characteristics of the Study Population
Characteristic
All
MTHFR 677CrT Genotype
(Median [1st–99th Percentile])
P for
trendMean
Median
(1st–99th
Percentile)
CC
( )np 5,452
CT
( )np 4,299
TT
( )np 850
Age, years 56 55 (50–64) 55 (50–64) 55 (50–64) 55 (50–64) .11
Plasma tHcy, mmol/liter 10.8 10.2 (5.8–24.2) 9.9 (5.7–19.2) 10.4 (5.9–22.8) 11.2 (5.7–43.3) !.001
Serum folate, nmol/liter 17.1 13.7 (4.7–59.8) 14.5 (5.2–60.8) 13.4 (4.8–59.9) 10.5 (3.5–50.1) !.001
Plasma riboﬂavin, nmol/liter 18.1 10.4 (3.0–135) 10.4 (3.0–150) 10.4 (2.8–135) 10.7 (2.8–119) .06
Serum cobalamin, pmol/liter 331 307 (128–732) 308 (127–734) 308 (130–730) 300 (113–766) .19
Plasma vitamin B6, nmol/liter 62.8 48.0 (12.7–295) 47.9 (13.3–280) 49.0 (12.6–336) 44.4 (11.9–286) .34
Plasma creatinine, mmol/liter 70 69 (44–105) 69 (44–106) 70 (45–104) 66 (45–101) .01
Most published work on B vitamins and homocysteine
has focused on folate and cobalamin in smaller studies,
which do not allow a comprehensive investigation of the
various components of the metabolic network related to
one-carbon metabolism. The present study included
10,601 middle-aged or elderly men and women from a
population-based cohort, and our aim was to assess the
MTHFR polymorphism and B vitamins as modulators of
one-carbon metabolism, with use of plasma tHcy as the
main outcome measure.
Subjects and Methods
Subjects and Study Design
The Norwegian Colorectal Cancer Prevention (NORCCAP) cohort
was established to study the utility of sigmoidoscopy and occult
blood testing as screening modalities for early detection of co-
lorectal cancer in men and women aged 50–64 years.26 Study
subjects were randomly selected from the population registries
in the city of Oslo and the county of Telemark and were included
from 1999 to 2001. The study was approved by the Regional
Ethics Committee and the Data Inspectorate. The procedures fol-
lowed were in accordance with theHelsinki Declaration, andwrit-
ten informed consent was obtained from all participants.
Biochemical Analyses
Whole blood collected into EDTA tubes was immediately put on
ice and was centrifuged at 11,000 g for 10 min to obtain plasma.
Blood samples collected into serum tubes without additives were
allowed to clot at room temperature and were centrifuged within
1 h. Plasma and serum samples were stored at 80C until anal-
ysis. tHcy was analyzed in plasma by gas chromatography–mass
spectrometry,27 whereas riboﬂavin, vitamin B6 (pyridoxal-5′-
phosphate), and creatinine were analyzed in plasma by liquid
chromatography–tandem mass spectrometry.28 Folate29 and co-
balamin30 were determined in serum by microbiologicalmethods.
MTHFR 677CrT genotypingwas performed by real-timePCRwith
5V exonuclease (Taqman) probes.31
Statistical Methods
Means and medians with percentiles were used for descriptive
statistics. Correlation analyses were performed using partial
Spearman correlation coefﬁcients adjusted for sex, age, and study
center. The x2 test was used to compare proportions.
We used simple linear regression models and models with mul-
tiple adjustments to identify predictors of tHcy. Independent var-
iables were represented in the model as indicator variables de-
noting membership in two or more categories for sex, age, the
MTHFR 677CrT polymorphism, folate, riboﬂavin, cobalamin, vi-
tamin B6, and creatinine. Thus, the regression coefﬁcients esti-
mated the difference in mean tHcy between the chosen reference
category and the other categories for each factor. Concentrations
of tHcy across categories of each factor were tested for linear
trend.
We investigated the possible interaction between MTHFR
677CrT genotype and other tHcy predictors, by including prod-
uct terms between genotype and each predictor in a multiple
linear regression model with tHcy as the dependent variable, re-
taining the main effects of all variables in the model. Further-
more, the data were presented according to MTHFR genotype and
B vitamin concentrations, and the regression analyses were per-
formed separately for the CC, CT, and TT genotypes, at concen-
trations of folate, riboﬂavin, cobalamin, and vitamin B6 below
and above the median. All statistical analyses were performed by
SPSS version 11.0. Tests were two-tailed, and P values !.05 were
considered statistically signiﬁcant.
Results
Population Characteristics and Blood Indices
The study population ( , 49% male) was pre-np 10,601
dominantly white (198%) and had a mean age of 56 years
(table 1). MTHFR 677CrT genotype frequencies were
50.3% (CC), 41.3% (CT), and 8.3% (TT) for men and
52.5% (CC), 39.8% (CT), and 7.7% (TT) for women. The
genotype distribution was in Hardy-Weinberg equilibrium
for each sex and for the whole study group ( ).MeanP .69
concentrations of metabolites and vitamins measured for
all genotypes combined were 10.8 mmol/liter for plasma
tHcy, 17.1 nmol/liter for serum folate, 18.1 nmol/liter for
plasma riboﬂavin, 331 pmol/liter for serum cobalamin,
62.8 nmol/liter for plasma vitamin B6, and 70 mmol/liter
for plasma creatinine (table 1). Plasma tHcy was higher in
subjects with the T allele as compared with the wild type.
In subjects with plasma tHcy 20 mmol/liter ( ),np 209
the prevalence of the TT genotype was 48% (data not
shown). Serum folate decreased according to the number
of T alleles. Concentrations of riboﬂavin, cobalamin, and
vitamin B6 were independent of genotype (table 1).
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Table 2. Spearman Correlation Coefﬁcients
Variable
and Genotype tHcy Folate Riboﬂavin Cobalamin
Folate: .44
CC .38
CT .45
TT .58
Riboﬂavin: .18 .26
CC .15 .23
CT .19 .28
TT .38 .35
Cobalamin: .24 .16 .20
CC .23 .14 .19
CT .25 .19 .22
TT .28 .16 .17
Vitamin B6: .24 .39 .35 .18
CC .20 .35 .34 .16
CT .24 .41 .36 .20
TT .38 .47 .43 .17
NOTE.—Nonparametric Spearman correlation coefﬁcients
adjusted for sex, age, and study center are shown for the
entire population ( ) and separately for the MTHFRnp 10,570
677CC ( ), 677CT ( ), and 677TT (np 5,433 np 4,282 np
) genotypes. All correlations were highly signiﬁcant843
( ).P ! .001
Correlations
Simple relationships between variables were calculated as
nonparametric Spearman correlation coefﬁcients, which
were adjusted for sex, age, and study center. Concentra-
tions of several B vitamins were positively related (table
2). The riboﬂavin-folate and the vitamin B6–folate rela-
tionships were modiﬁed by MTHFR genotype. Plasma tHcy
was inversely related to all B vitamins, and the tHcy–B
vitamin relationships were modiﬁed by the MTHFR poly-
morphism and were strongest in subjects with the TT
genotype, particularly for folate and riboﬂavin (table 2).
A positive relationship ( ) was observed betweenrp 0.21
tHcy and creatinine.
The MTHFR 677CrT Polymorphism and B Vitamins as
tHcy Predictors
The MTHFR polymorphism, folate, riboﬂavin, cobalamin,
vitamin B6, and creatinine were independently related to
plasma tHcy in regression models adjusted for sex, age,
and study center ( ; data not shown) and in modelsP ! .001
with multiple adjustments ( ) (table 3).P ! .001
The estimated difference in mean plasma tHcy between
subjects with the TT genotype compared with the CC ge-
notype was 2.4 mmol/liter (table 3). Folate was a strong
tHcy predictor, and tHcy was 3.0 mmol/liter higher in sub-
jects in the lowest compared with the highest quartile of
folate concentrations (table 3). MTHFR genotype strongly
modiﬁed folate effects, and, in TT subjects, plasma tHcy
was 5.4 mmol/liter higher in the lowest compared with the
highest folate quartile.
Riboﬂavin was only a weak tHcy predictor in subjects
with the CC and CT genotypes, but, in the TT group,
riboﬂavin was the second strongest tHcy predictor, and
the difference between extreme riboﬂavin quartiles was
4.1 mmol/liter of plasma tHcy (table 3).
The cobalamin-tHcy and vitamin B6–tHcy relationships
were similarly but less strongly related to genotype. The
tHcy difference between extreme vitamin quartiles in sub-
jects with the TT genotype was 3.2 mmol/liter for cobal-
amin and 2.1 mmol/liter for vitamin B6 (table 3). Sex, but
not age or creatinine, interacted with genotype.
Modiﬁcation of the MTHFR Genotype–tHcy Relationship by
B Vitamins
Predictors of plasma tHcy were studied in subjects with
the CC, CT, and TT genotypes at folate concentrations
below and above the median, with the use of regression
models with multiple adjustments (ﬁg. 1). There was an
inverse relationship between riboﬂavin and plasma tHcy,
which was modiﬁed by MTHFR genotype, both at low and
high folate concentrations (ﬁg. 1). The relationship was
strongest at low folate levels, however, and, for subjects
in the TT group, the estimated tHcy difference between
extreme riboﬂavin quartiles was 5.0 mmol/liter, whereas
the corresponding difference was 1.8 mmol/liter at high
folate levels. At low folate levels, cobalamin was also
strongly and inversely related to tHcy (ﬁg. 1). At high
folate concentrations, this relationship was dramatically
weakened, particularly in the TT group. Vitamin B6 was
related to tHcy both at low and high folate concentrations,
but at high folate levels no genotype effect was observed
(ﬁg. 1).
MTHFR genotype and B vitamin effects were similarly
studied at concentrations of plasma riboﬂavin below and
above the median (ﬁg. 2). Folate was robustly related to
plasma tHcy, both at low and high riboﬂavin concentra-
tions, but high riboﬂavin levels weakened the folate-tHcy
relationship in subjects with the TT genotype. Cobalamin
was related to plasma tHcy at low and high riboﬂavin
levels, but the relationship was much weaker and was not
signiﬁcantly modiﬁed by genotype when riboﬂavin levels
were high (ﬁg. 2). Vitamin B6 was moderately related to
plasma tHcy at low and high riboﬂavin levels, particularly
in subjects with the variant enzyme, but the genotype
dependency of the vitamin B6–tHcy relationship was
weaker when riboﬂavin levels were high.
Concentrations of cobalamin below and above the me-
dian had a similar but less pronounced effect on the folate-
tHcy, riboﬂavin-tHcy, and vitamin B6–tHcy relationships
in subjects with different MTHFR genotypes (ﬁg. 3). High
levels of cobalamin weakened the genotype dependency
of the B vitamin–tHcy associations. Vitamin B6 had a sim-
ilar impact on the effects of other B vitamins and the
MTHFR genotype (ﬁg. 4). Folate, riboﬂavin, and cobalamin
were determinants of plasma tHcy both at low and high
levels of vitamin B6, but high levels of vitamin B6 atten-
uated the relationships between the other B vitamins and
Table 3. Determinants of Plasma tHcy according to MTHFR 677CrT Genotype
Variable
MTHFR Genotype
All
CC
( )np 5,452
CT
( )np 4,299
TT
( )np 850
Interaction
Term (P)b
Estimated
tHcy
Differencea
P for
trend
Estimated
tHcy
Differencea
P for
trend
Estimated
tHcy
Differencea
P for
trend
Estimated tHcy
Differencea
P for
trend
Sex (vs. female; ):np 5,386
Male ( )np 5,213 .4 (.2–.5) !.001 .3 (.1–.5) !.001 .4 (.2–.6) !.001 1.0 (.1–2.0) .13 .04
Age, years (vs. 50–53; ):np 2,540
54–55 ( )np 3,052 .5 (.3–.7) .5 (.4–.7) .4 (.1–.6) 1.0 (.2–2.2)
56–59 ( )np 2,637 .7 (.5–.9) !.001 .7 (.5–.9) !.001 .7 (.4–1.0) !.001 .5 (.7–1.7) .16 .34
60–64 ( )np 2,370 1.2 (1.0–1.3) 1.2 (1.0–1.4) 1.0 (.8–1.3) 1.5 (.2–2.7)
Serum folate, nmol/liter (vs. 20.2–151; ):np 2,647
13.7–20.2 ( )np 2,647 .8 (.6–1.0) .8 (.6–1.0) .9 (.6–1.1) 1.3 (.2–2.9)
10.1–13.7 ( )np 2,646 1.2 (1.0–1.4) !.001 1.3 (1.1–1.5) ! .001 1.3 (1.0–1.6) !.001 1.1 (.4–2.7) !.001 !.001
1.5–10.1 ( )np 2,651 3.0 (2.8–3.2) 2.3 (2.1–2.5) 3.0 (2.7–3.3) 5.4 (4.0–6.8)
Plasma riboﬂavin, nmol/liter (vs. 18.1–596; ):np 2,644
10.4–18.1 ( )np 2,656 .1 (.1–.3) .1 (.1–.3) .0 (.3–.3) .1 (1.4–1.1)
6.8–10.4 ( )np 2,649 .2 (.0–.4) !.001 .1 (.1–.3) ! .001 .2 (.1–.5) !.001 1.0 (.2–2.3) !.001 !.001
.9–6.8 ( )np 2,652 .8 (.6–1.0) .4 (.2–.6) .7 (.4–.9) 4.1 (2.7–5.5)
Serum cobalamin, pmol/liter (vs. 380–6,500; ):np 2,644
307–380 ( )np 2,650 .3 (.1–.5) .2 (.0–.4) .5 (.2–.7) .6 (.7–1.8)
245–307 ( )np 2,646 .5 (.3–.7) !.001 .4 (.2–.5) !.001 .6 (.3–.8) !.001 1.4 (.1–2.6) !.001 !.001
34–245 ( )np 2,645 1.5 (1.3–1.6) 1.2 (1.0–1.4) 1.5 (1.3–1.8) 3.2 (2.0–4.5)
Plasma vitamin B6, nmol/liter (vs. 73.2–1,093; ):np 2,651
48.0–73.1 ( )np 2,655 .1 (.1–.3) .2 (.0–.4) .1 (.2–.4) .5 (1.9–.8)
32.6–47.9 ( )np 2,642 .1 (.1–.3) !.001 .2 (.0–.4) !.001 .0 (.3–.3) !.01 .4 (1.8–1.0) .01 .006
4.3–32.6 ( )np 2,653 .7 (.5–.9) .5 (.3–.8) .5 (.2–.8) 2.1 (.6–3.7)
Serum creatinine, mmol/liter (vs. 30–61; ):np 2,650
61–69 ( )np 2,646 .3 (.1–.5) .5 (.3–.7) .1 (.1–.4) .4 (.8–1.5)
69–78 ( )np 2,659 .8 (.7–1.0) !.001 1.0 (.8–1.2) !.001 .5 (.2–.8) !.001 1.5 (.2–2.9) .003 .29
78–571 ( )np 2,645 1.7 (1.5–1.9) 1.8 (1.6–2.0) 1.5 (1.2–1.8) 2.5 (1.0–4.0)
MTHFR 667CrT genotype (vs. CC; ):np 5,254
CT ( )np 4,299 .4 (.3–.5) !.001
TT ( )np 850 2.4 (2.2–2.6)
NOTE.—Data were analyzed by multiple regression with tHcy as the dependent variable. All variables in the table and study center were included in the model.
a Values are given as means (95% CIs), in mmol/liter.
b P for the product term between MTHFR genotype and the various tHcy predictors.
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Figure 1. B vitamins as determinants of plasma tHcy according to folate concentrations and MTHFR 677CrT genotype. The population
was stratiﬁed according to levels of serum folate (below and above the median) and MTHFR 677CrT genotype. The riboﬂavin-tHcy,
cobalamin-tHcy, and vitamin B6–tHcy relationships were then studied in a regression model, which included these vitamins in addition
to sex, age, creatinine, and study center. Means with upper limits of 95% CIs and P for trend across quartiles are shown in each panel.
Nutrient-gene interaction terms were calculated as the product between MTHFR genotype and the various B vitamins.
tHcy, and the cobalamin-tHcy relationship showed no ge-
notype dependency at high vitamin B6 levels.
Discussion
We studied the MTHFR 677CrT polymorphism and sev-
eral B vitamins that are involved in one-carbon metabo-
lism in a large population-based cohort ( ), us-np 10,601
ing plasma tHcy as the main outcome measure. The
MTHFR polymorphism, folate, riboﬂavin, cobalamin, and
vitamin B6 were independently related to plasma tHcy.
The MTHFR polymorphism had the strongest impact
when B vitamin levels were low. Conversely, MTHFR ge-
notype modiﬁed B vitamin–tHcy relationships, which
were strongest in subjects with the T allele, particularly
for folate and riboﬂavin. Finally, interactions between B
vitamins were observed, and B vitamin–tHcy relationships
were stronger when concentrations of other B vitamins
were low.
Study Design
The large study population allowed us to investigate sub-
groups and to obtain precise estimates of MTHFR 677CrT
polymorphism and B vitamin effects. The homogeneity
of the study population with respect to age and ethnicity
reduced the potential for confounding from these vari-
ables. B vitamin status was determined in blood. The re-
lationship between the estimated intake of folate and vi-
tamin B6 and blood vitamin concentrations is relatively
strong, with an adjusted correlation coefﬁcient in the
range 0.5–0.6.32,33 Circulating vitamin B12 shows a some-
what weaker relationship to intake data, whichmay reﬂect
impaired absorption in the elderly.32
The distribution of MTHFR genotypes may be assumed
to be unrelated to diet and lifestyle factors. Therefore, the
investigation of phenotypic effects of the MTHFR poly-
morphism provides a means for reducing the effect of con-
founders that may distort interpretations of conventional
observational studies.34,35 A similar approach was used for
the investigation of B vitamin effects. Although B vitamin
status may be related to lifestyle,36 the problem of con-
founding may be reduced by assessing B vitamin effects
across subgroups deﬁned by genotype.
MTHFR 677CrT Genotype and Blood Indices
The T allele frequency was ∼0.3, which accords well with
previous reports from population-based studies in north-
ern Europe.37 Concentrations of plasma tHcy and B vita-
mins were comparable to those reported in other stud-
ies.28,38,39 The concentration of plasma tHcy increased, and
folate decreased, according to the number of T alleles, as
has been shown by others.40
B Vitamin Interrelationships
Spearman correlation studies showed that B vitaminswere
positively related to each other, as has been shown else-
where.38 Such a positive relationship may be caused by
common dietary sources for B vitamins41 or may be ex-
plained by the fact that the metabolism of several B vi-
tamins depends on other B vitamins.1,42,43 A novel ﬁnding
is that the riboﬂavin-folate relationship was MTHFR ge-
notype–dependent. The variant enzyme associated with
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Figure 2. B vitamins as determinants of plasma tHcy according to riboﬂavin concentrations and MTHFR 677CrT genotype. The
population was stratiﬁed according to levels of plasma riboﬂavin (below and above the median) and MTHFR 677CrT genotype. The
folate-tHcy, cobalamin-tHcy, and vitamin B6–tHcy relationships were then studied in a regression model, which included these vitamins
in addition to sex, age, creatinine, and study center. Means with upper limits of 95% CIs and P for trend across quartiles are shown
in each panel. Nutrient-gene interaction terms were calculated as the product between MTHFR genotype and the various B vitamins.
the 677CrT transition of the MTHFR gene has lower af-
ﬁnity for its ﬂavin cofactor than the wild-type enzyme.44,45
Thus, the variant enzyme might depend on higher con-
centrations of riboﬂavin for sufﬁcient catalytic activity. An
inadequate riboﬂavin status might therefore reduce the
formation of 5-methyltetrahydrofolate, the prevailing fo-
late species in serum.11
MTHFR Genotype and B Vitamins as Modulators of One-
Carbon Metabolism
The MTHFR 677CrT polymorphism was an independent
predictor of plasma tHcy. This association was modiﬁed
by several B vitamins, particularly folate and riboﬂavin,
and the impact of the T allele was strongest when B vita-
mins were low. The folate-MTHFR40 and riboﬂavin-MTHFR38
relationships provide a paradigm of nutrient-gene inter-
actions,46 which may be explained by the role of riboﬂavin
as cofactor for MTHFR,1,45 whereas folate serves as a sub-
strate for MTHFR and stabilizes the enzyme.45
Other B vitamins displayed similar but somewhat
weaker interactions with the MTHFR polymorphism than
folate and riboﬂavin. A genotype dependency of the co-
balamin-tHcy relationship has been reported in one
study.47 Cobalamin serves as the cofactor for methionine
synthase, which uses the product of the MTHFR reaction,
5-methyltetrahydrofolate, as a cosubstrate. Vitamin B6 is
the cofactor for serine hydroxymethyltransferase, which
forms 5,10-methylenetetrahydrofolate, the MTHFR sub-
strate,2,4,5 and is also involved in homocysteine transsul-
furation.5 Thus, cobalamin and vitamin B6 might be ex-
pected to have an impact on the metabolic network of
which MTHFR is a part.
B vitamins not only modify the phenotypic expression
of the MTHFR 677CrT polymorphism but are tHcy pre-
dictors in their own right. This has consistently been
shown in several studies for folate39,48 and cobalamin,39,49
whereas the highly MTHFR genotype–dependent riboﬂa-
vin-tHcy relationship was demonstratedmore recently.38,50
Several studies show that vitamin B6 is a strong deter-
minant of plasma tHcy in human subjects after methio-
nine loading.5,51 However, data on the vitamin B6–tHcy
relationship in subjects who have not undergone methi-
onine loading are less consistent; some,52 but not all,53,54
studies report that vitamin B6 is an independent deter-
minant of plasma tHcy. Our study shows that the vitamin
B6–tHcy relationship is largely driven by the TT group,
which comprises only 10% of most populations of Asian
or European descent,37 and this may explain why a rela-
tionship between vitamin B6 and plasma tHcy has not
been observed in smaller studies. In addition, interactions
between vitamin B6 and other B vitamins might explain
apparent inconsistencies between studies on vitamin B6
and tHcy, because B vitamin status may vary between
study populations.
Implications
At present, plasma tHcy is an established marker of folate
and cobalamin status and may be used for the diagnosis
and follow-up of deﬁciency states.39,48,49 Our data indicate
that elevated tHcy may also reﬂect impaired riboﬂavin or
vitamin B6 status, particularly in individuals with the TT
genotype. Because a large fraction of hyperhomocystei-
nemic subjects have the TT genotype,55 deﬁciencies of
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Figure 3. B vitamins as determinants of plasma tHcy according to cobalamin concentrations and MTHFR 677CrT genotype. The
population was stratiﬁed according to levels of serum cobalamin (below and above the median) and MTHFR 677CrT genotype. The
folate-tHcy, riboﬂavin-tHcy, and vitamin B6–tHcy relationships were then studied in a regression model, which included these vitamins
in addition to sex, creatinine, and study center. Means with upper limits of 95% CIs and P for trend across quartiles are shown in each
panel. Nutrient-gene interaction terms were calculated as the product between MTHFR genotype and the various B vitamins.
these vitamins may be an important cause of moderate
hyperhomocysteinemia.
Our results indicate the existence of a functional met-
abolic network including the MTHFR enzyme and several
B vitamins, which suggests that physiological and bal-
anced regimes may be needed for the treatment of B vi-
tamin deﬁciencies and for B vitamin intervention trials.
In pernicious anemia, folate treatment may effectively re-
duce plasma tHcy even though underlying metabolic de-
rangements may progress if cobalamin is not also given.56
B vitamin intervention trials designed to assess the impact
of plasma tHcy–lowering treatment on cardiovascular dis-
ease risk have generally been negative.25,57 Most studies
have included only folic acid and vitamin B6, however,
and more balanced regimens including several B vitamins
at physiological doses may be needed to optimize such
trials.58
We found that the MTHFR 677CrT polymorphism and
B vitamins were interactive modulators of the metabolism
of homocysteine, which is an important intermediate in
the transfer of one-carbon units. Diseases that might be
caused by derangements of one-carbon metabolismmight
similarly depend on MTHFR genotype and B vitamins. Sev-
eral studies support this idea, and low blood concentra-
tions of folate strengthen the association between the
MTHFR polymorphism and the risk of cardiovascular dis-
ease.10 The MTHFR polymorphism is apparently a weaker
predictor of coronary heart disease in American than in
European populations,10,59 and this might be explained by
mandatory B vitamin fortiﬁcation of food items in the
United States,60 which predictably increases the dietary
intake of riboﬂavin and folate.
Blood concentrations of folate also modulate the impact
of the MTHFR polymorphism, with respect to the risk of
colorectal cancer.13,15 The relationship between MTHFR ge-
notype and colorectal cancer may also be modiﬁed by
cobalamin15 and vitamin B6.15,61 Several studies report an
interaction between the MTHFR polymorphism and folate
as risk factors of colorectal adenoma.62,63 Moreover, inter-
actions between MTHFR genotype and B vitamins have
been observed in studies on intermediary endpoints that
may be related to the development of cancer. Some studies
show that the MTHFR 677CrT polymorphism and folate
status are interactive determinants of DNA methylation
in human leukocytes64–66 and of the incorporation of one-
carbon units into monocyte DNA.67
Conclusions
The present study provides comprehensive metabolic data
from a population-based cohort and has sufﬁcient statis-
tical power to give a detailed record of the relationship
between MTHFR and several B vitamins, which form a
network with major effects on the transfer of one-carbon
units. B vitamins strongly modiﬁed genotype effects and
vice versa. Individuals with the TT genotype were partic-
ularly sensitive to the status of several B vitamins and
might be candidates for personalized nutritional recom-
mendations. Our results corroborate and extend obser-
vations from in vitro studies and shed light on published
data on the MTHFR polymorphism and B vitamins as de-
terminants of plasma tHcy and chronic diseases. Aware-
ness of the cooperativity between B vitamins involved in
one-carbon metabolism should provide guidance on the
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Figure 4. B vitamins as determinants of plasma tHcy according to vitamin B6 concentrations and MTHFR 677CrT genotype. The
population was stratiﬁed according to levels of plasma vitamin B6 (below and above the median) and MTHFR 677CrT genotype. The
folate-tHcy, riboﬂavin-tHcy, and cobalamin-tHcy relationships were then studied in a regression model, which included these vitamins
in addition to sex, age, creatinine, and study center. Means with upper limits of 95% CIs and P for trend across quartiles are shown
in each panel. Nutrient-gene interaction terms were calculated as the product between MTHFR genotype and the various B vitamins.
design of B vitamin regimens to be used in future inter-
vention trials.
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